Kardigan, Inc.(KARD)

Biotechnology · Princeton, NJ

$12.58-2.66 (-17.45%)

Delayed quote: Oct 6, 2026, 10:35 AM EDT

Kardigan (KARD) EV/Sales: History & Chart | TGMCharts

EV/Sales Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/Sales ratio is N/A as of 2026-10-06T14:42:28.327Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:42:28.327Z.

Quote observation: 2026-10-06T14:40:16.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,148,007,705
Total debt · period ending 2026-06-30: 13,347,000
Cash · period ending 2026-06-30: 384,005,000
TTM revenue · period ending 2026-06-30: N/A

FMP input reference: 6dd2a4984e4340952b62e9ecd156f35eed99e3c78779d37ae6f95d3f5c845125

EV/EBITDA|P/S Ratio|Revenue|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

KARD EV/Sales Ratio Metrics

EV/SALES RATIO

N/A

KARD Competitors' EV/Sales Ratio

KARD

Kardigan, Inc.

Current

Market Cap

$1.15B

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AVLN

Avalyn Pharma Inc. Common Stock

vs KARD

Market Cap

$1.13B

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DMRA

Damora Therapeutics, Inc.

vs KARD

Market Cap

$1.13B

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HROW

Harrow Health, Inc.

vs KARD

Market Cap

$1.11B

EV/Sales Ratio

4.83x

TTM Avg

6.64x

3Y Avg

6.66x

5Y Avg

5.94x

GDRX

GoodRx Holdings, Inc.

vs KARD

Market Cap

$1.16B

EV/Sales Ratio

1.78x

TTM Avg

1.60x

3Y Avg

2.60x

5Y Avg

4.51x

AMPH

Amphastar Pharmaceuticals, Inc.

vs KARD

Market Cap

$1.11B

EV/Sales Ratio

2.15x

TTM Avg

2.15x

3Y Avg

3.23x

5Y Avg

3.44x

NKTR

Nektar Therapeutics

vs KARD

Market Cap

$1.17B

EV/Sales Ratio

23.23x

TTM Avg

24.63x

3Y Avg

10.61x

5Y Avg

10.20x

BCAX

Bicara Therapeutics Inc. Common Stock

vs KARD

Market Cap

$1.09B

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IRMD

IRadimed Corporation

vs KARD

Market Cap

$1.09B

EV/Sales Ratio

11.90x

TTM Avg

13.52x

3Y Avg

10.24x

5Y Avg

9.95x

MNKD

MannKind Corporation

vs KARD

Market Cap

$1.19B

EV/Sales Ratio

3.72x

TTM Avg

4.64x

3Y Avg

5.92x

5Y Avg

9.62x

NAME	MARKET CAP	EV/SALES RATIO	TTM	3Y	5Y
Kardigan, Inc. (KARD)	$1.15B	N/A	N/A	N/A	N/A
Avalyn Pharma Inc. Common Stock (AVLN)vs ›	$1.13B	N/A	N/A	N/A	N/A
Damora Therapeutics, Inc. (DMRA)vs ›	$1.13B	N/A	N/A	N/A	N/A
Harrow Health, Inc. (HROW)vs ›	$1.11B	4.83x	6.64x	6.66x	5.94x
GoodRx Holdings, Inc. (GDRX)vs ›	$1.16B	1.78x	1.60x	2.60x	4.51x
Amphastar Pharmaceuticals, Inc. (AMPH)vs ›	$1.11B	2.15x	2.15x	3.23x	3.44x
Nektar Therapeutics (NKTR)vs ›	$1.17B	23.23x	24.63x	10.61x	10.20x
Bicara Therapeutics Inc. Common Stock (BCAX)vs ›	$1.09B	N/A	N/A	N/A	N/A
IRadimed Corporation (IRMD)vs ›	$1.09B	11.90x	13.52x	10.24x	9.95x
MannKind Corporation (MNKD)vs ›	$1.19B	3.72x	4.64x	5.92x	9.62x

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

It works for unprofitable companies where P/E doesn't apply
Revenue is harder to manipulate than earnings
It supports comparisons across companies at different profitability stages
It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA P/S Ratio Revenue All Metrics